KRON
vs
S&P 500
KRON
S&P 500
Over the past 12 months, KRON has underperformed S&P 500, delivering a return of +13% compared to the S&P 500's +27% growth.
Stocks Performance
KRON vs S&P 500
Performance Gap
KRON vs S&P 500
Performance By Year
KRON vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kronos Bio Inc
Glance View
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).
